Cartalax

Synonyms: Cartalax peptide, Articular cartilage peptide, Cartilage peptide complex, CAS 231102-99-3

Cartalax is a synthetic peptide fragment derived from the amino acid sequence of type II collagen, a key structural protein of articular cartilage. It is produced by solid-phase peptide synthesis and supplied as a high-purity lyophilized powder, designed for research and formulation development in the field of musculoskeletal health. The peptide corresponds to a specific region of the collagen triple helix that has been identified as a bioactive motif capable of interacting with chondrocytes and modulating cartilage metabolism.

Unlike generic collagen hydrolysates, Cartalax is a sequence-defined peptide with a molecular weight of 328.36 g/mol. Its small size and hydrophilic nature allow for efficient penetration into cartilage matrix in vitro and rapid dissolution in aqueous media, making it a valuable tool for studying cartilage regeneration and joint health. The peptide’s activity is attributed to its ability to mimic the natural signaling cues of intact collagen, thereby supporting anabolic processes in chondrocytes and helping to maintain extracellular matrix integrity.

In the B2B arena, Cartalax is primarily used as an active pharmaceutical ingredient (API) or as a key component in nutraceutical formulations targeting joint comfort and mobility. It is also employed as a reference standard in analytical laboratories and as a research reagent for investigating cartilage biology and osteoarthritis pathways. Our production follows strict quality control protocols to ensure batch-to-batch consistency, with each lot accompanied by a comprehensive certificate of analysis.

Function

• Chondroprotective effect: Helps protect articular cartilage from degradation by inhibiting matrix metalloproteinases.
• Stimulation of collagen synthesis: Promotes the production of type II collagen and proteoglycans by chondrocytes.
• Anti-inflammatory activity: Reduces the expression of inflammatory cytokines such as IL-1β and TNF-α in joint tissues.
• Joint mobility support: May improve joint comfort and flexibility in preclinical models.
• Cartilage repair: Supports the regeneration of damaged cartilage matrix.

Source & Standardization

• Source: Synthetic peptide derived from human type II collagen sequence.
• Production: Solid-phase peptide synthesis (SPPS), followed by HPLC purification and lyophilization.
• Standardization: ≥98% purity by HPLC; identity confirmed by mass spectrometry.
• Forms: White to off-white lyophilized powder.
• Applications: Nutraceutical supplements, pharmaceutical research, cell culture studies, analytical standards.

Specifications

Documentation & Supply

• Monthly capacity: 500 kg
• Lead time: 3-5 business days (stock items)
• Documentation: COA, MSDS, TDS, and additional technical support available upon request.
• Packaging: 1 g, 5 g, 10 g in sealed vials; bulk quantities in food-grade containers.

Request For Quote

• LyvBio Co., Ltd. — Email: info@lyvbio.com